Resolution Biosciences
The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.
Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Resolution Bio Seeks to Widen Private Payor Coverage Following Lung Cancer Liquid Biopsy Launch
Premium
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.